Book a Meeting

ADCC-Enhanced Anti-Human GD2 (Naxitamab) Antibody (CAT#: BioBet-CB-004LX) Datasheet

Target
GD2
Isotype
IgG1
Description
ADCC-Enhanced Anti-Human GD2 (Naxitamab) Antibody is a glycosylation-modified anti- therapeutic antibody.
Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced GD2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
GD2
Full Name
glucagon receptor
Background
GD2 is a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues, principally to the cerebellum and peripheral nerves in humans. The relatively tumor specific expression of GD2 makes it a suitable target for immunotherapy with monoclonal antibodies or with artificial T cell receptors.
Alternative Names
GD2 ganglioside; GD2
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Naxitamab
Host
Humanized
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human GD2 (Naxitamab) Antibody is derived from clone Naxitamab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the GD2, and it is intended for the research of High-risk neuroblastoma and refractory osteomedullary disease.
Indication
High-risk neuroblastoma and refractory osteomedullary disease

Similar to the parental antibody Naxitamab, ADCC-Enhanced Anti-Human GD2 (Naxitamab) Antibody targets to the antigen GD2, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.

Related Products

Non-fucosylated Anti-Human GD2 (Dinutuximab) Therapeutic Antibody (CAT#: BioBet-019ZP)
Non-Fucosylated Anti-Human GD2 (Naxitamab) Therapeutic Antibody (CAT#: BioBet-1821ZP)
Highly Galactosylated Anti-GD2 (Dinutuximab) Antibody (CAT#: BioBet-GA-019ZP)
BetterBet™ Anti-GD2 FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP329)
BetterBet™ Anti-GD2 Recycling Antibody (CAT#: AES-0622-ZP1)
BetterBet™ Anti-GD2 On-Target Antibody (CAT#: AES-0622-ZP657)
BetterBet™ Anti-GD2 Half-Life Extended Antibody (CAT#: AES-0622-ZP985)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany